PCRX · NASDAQ
Pacira BioSciences (PCRX) Stock Price & Fundamentals
Pacira BioSciences (PCRX) closed at $518.44 on Oct 9, 2026, up 0.88% from the previous close of $513.93.
Share price, past year
1Y −2.73%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $518.44 |
| Sep 30, 2026 | $524.68 |
| Aug 31, 2026 | $561.12 |
| Jul 31, 2026 | $558.77 |
| Jun 30, 2026 | $530.08 |
| May 29, 2026 | $545.26 |
| Apr 30, 2026 | $519.27 |
| Mar 31, 2026 | $512.33 |
| Feb 27, 2026 | $495.89 |
| Jan 30, 2026 | $513.34 |
| Dec 31, 2025 | $520.36 |
| Nov 28, 2025 | $537.98 |
| Oct 31, 2025 | $530.49 |
Key statistics
- Market cap
- $20.65B
- P/E (TTM)
- 1,440.1
- EPS (TTM)
- $0.36
- Revenue (TTM)
- $746.16M
- Net income (TTM)
- $14.64M
- Shares outstanding
- 39.8M
- Dividend yield
- —
- 52-week range
- $492.52 – $580.37
Pacira BioSciences's market cap is $20.65B, based on a share price of $518.44 and 39.8M shares outstanding as of Jun 30, 2026.
Financials
Pacira BioSciences reported revenue of $726.41M for fiscal 2025, up 3.63% from fiscal 2024.
Pacira BioSciences earned net income of $7.03M in fiscal 2025, a net margin of 1.0%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $726.41M | +3.6% | $7.03M | 1.0% | $0.16 | $136.66M |
| FY2024ended Dec 31, 2024 | $700.97M | +3.9% | −$99.56M | −14.2% | −$2.15 | $178.75M |
| FY2023ended Dec 31, 2023 | $674.98M | +1.2% | $41.96M | 6.2% | $0.89 | $139.49M |
| FY2022ended Dec 31, 2022 | $666.82M | +23.1% | $15.91M | 2.4% | $0.34 | $115.20M |
| FY2021ended Dec 31, 2021 | $541.53M | +26.0% | $41.98M | 7.8% | $0.92 | $79.85M |
| FY2020ended Dec 31, 2020 | $429.65M | +2.1% | $145.52M | 33.9% | $3.33 | $39.23M |
| FY2019ended Dec 31, 2019 | $421.03M | +24.8% | −$11.02M | −2.6% | −$0.27 | $60.36M |
| FY2018ended Dec 31, 2018 | $337.28M | +17.7% | −$471.00K | −0.1% | −$0.01 | $34.36M |
| FY2017ended Dec 31, 2017 | $286.63M | +3.7% | −$42.61M | −14.9% | −$1.07 | −$1.48M |
| FY2016ended Dec 31, 2016 | $276.37M | — | −$37.95M | −13.7% | −$1.02 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $192.40M | $4.65M | $0.12 |
| Q1 FY2026ended Mar 31, 2026 | $177.38M | $2.92M | $0.07 |
| Q4 FY2025ended Dec 31, 2025 | $196.87M | $1.64M | $0.05 |
| Q3 FY2025ended Sep 30, 2025 | $179.52M | $5.43M | $0.12 |
| Q2 FY2025ended Jun 30, 2025 | $181.10M | −$4.85M | −$0.11 |
| Q1 FY2025ended Mar 31, 2025 | $168.92M | $4.81M | $0.10 |
| Q4 FY2024ended Dec 31, 2024 | $187.25M | $16.04M | $0.38 |
| Q3 FY2024ended Sep 30, 2024 | $168.57M | −$143.47M | −$3.11 |
Company profile
- Name
- Pacira BioSciences, Inc.
- Ticker
- PCRX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2000 Sierra Point Parkway, Suite 900, Brisbane, CA 94005
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001396814
Recent SEC filings
- Oct 8, 2026
- Aug 4, 2026
- Aug 4, 2026
- Jun 30, 2026
- Jun 11, 2026
- Apr 30, 2026
- Apr 30, 2026
- Feb 26, 2026
Frequently asked questions
What is Pacira BioSciences's stock price?
Pacira BioSciences (PCRX) closed at $518.44 on Oct 9, 2026, up 0.88% from the previous close of $513.93.
What is Pacira BioSciences's market cap?
Pacira BioSciences's market cap is $20.65B, based on a share price of $518.44 and 39.8M shares outstanding as of Jun 30, 2026.
How much revenue does Pacira BioSciences make?
Pacira BioSciences reported revenue of $726.41M for fiscal 2025, up 3.63% from fiscal 2024.
What is PCRX's P/E ratio?
Pacira BioSciences's price-to-earnings ratio is 1,440.1, based on trailing twelve-month diluted EPS of $0.36.
Does Pacira BioSciences pay a dividend?
Pacira BioSciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Pacira BioSciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures